Raman Process Monitoring Calibration Model Patents: Leaders & Trends 2026
- A fragmented field, not a monopoly. the leader holds 44 records and the top 5 combined account for only 13.8% of the 1,243 records in scope — most of the field sits with single- and few-filing entrants.
- Filing has cooled from its 2022 peak. annual output ran from 70 records in 2021 to 52 in 2024, a 26% decline over that span, after peaking at 90 records in 2022.
- Optics and material analysis dominate the claim space. G01N appears in 99.4% of records and G01J in 29.4%, while AI-based computation (G06N) appears in just 3.8% — a narrow, largely open seam between spectroscopy hardware and model-building software.
Filing growth compares 2021 (70 records) with 2024 (52) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 1,243 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This landscape tracks patent filings at the intersection of Raman spectroscopy hardware and calibration modelling practice — reference samples, calibration transfer, prediction error, validation sets, concentration ranges and model updates — across IPC classes covering optical spectroscopy (G01N21/65, G01N21/359) and enzymatic/DNA measurement (C12Q3/00). It spans 1,243 published records filed between 2015 and mid-2026.
The scope deliberately sits at the boundary between instrumentation claims and the statistical or software methods used to keep a calibration model valid as reference conditions drift, which is why bioprocessing, diagnostics and materials-analysis assignees all appear in the same ranking.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
Two views of the same 1,243-record corpus: annual filing volume, and the IPC subclasses those records carry.
Filing trend, 2017–2026
Filings rose from 52 records in 2017 to a peak of 90 in 2022, then eased to 52 by 2024 — a 26% decline over the 2021–2024 span. Note that 2025 and 2026 figures are still incomplete, since publication typically lags filing by around 18 months, so the most recent years understate true activity rather than signalling an accelerating drop.
IPC subclass composition
G01N (material analysis and testing) touches almost the entire corpus at 99.4% of records, with G01J (radiation and light measurement) present in 29.4%. Life-science-adjacent classes — A61B at 13.6%, C12Q at 6.3%, C12M at 3.4% — mark where Raman calibration work overlaps bioprocessing and diagnostics, while G06N at 3.8% shows AI-based model computation is still a minority claim element rather than the norm.
Shares are the percentage of the 1,243 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Raman Process Monitoring Calibration Model with Eureka
This page is one run against one query. Ask Eureka your own question about raman process monitoring calibration model and every answer comes back with the patent numbers behind it.
Try EurekaMost-cited records and a representative filing
A Raman spectroscopy integrated perfusion cell culture system for monitoring and auto-controlling perfusion cell culture
Filed by WuXi Biologics Ireland Limited, this application describes a bioreactor fitted with Raman probes immersed directly in the culture, feeding a host computer that monitors and auto-controls perfusion cell culture in real time. It ties spectroscopic measurement directly to bioprocess control rather than to offline analysis.Filed 2022-09-22 · US20220299370A1
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US5615673A | Apparatus and methods of raman spectroscopy for analysis of blood gases and analytes | 369 |
| 2 | US20040073120A1 | Systems and methods for spectroscopy of biological tissue | 329 |
| 3 | US6197503B1 | Integrated circuit biochip microsystem containing lens | 303 |
| 4 | US20040127777A1 | Indirect measurement of tissue analytes through tissue properties | 243 |
| 5 | US20040180379A1 | Surface-enhanced raman nanobiosensor | 224 |
| 6 | US6448064B1 | Integrated circuit biochip microsystem | 219 |
| 7 | US5850623A | Method for standardizing raman spectrometers to obtain stable and transferable calibrations | 216 |
| 8 | US9554738B1 | Spectroscopic tomography systems and methods for noninvasive detection and measurement of analytes using coll… | 178 |
| 9 | US6610351B2 | Raman-active taggants and their recognition | 174 |
| 10 | US5404218A | Fiber optic probe for light scattering measurements | 174 |
Citation counts favour older filings that have had more time to accumulate citations within the searched corpus — treat them as a signal of influence on the field, not of current commercial importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for a filing decision
Three patterns worth weighing before committing claim language in this space.
No single assignee controls the field
The leader holds 44 records and the top 5 combined account for 13.8% of the 1,243 records in scope; the top 10 reach 22.1%. That leaves the large majority of filings distributed across a long tail of entrants with just one or a handful of records each.
Volume has eased from its 2022 peak
Annual filings peaked at 90 records in 2022 and fell to 52 by 2024, a 26% decline over that three-year span. Because publication lags filing by roughly 18 months, 2025-2026 figures are still filling in and should not be read as a continued fall.
Model-side computation is thinly claimed
G01N and G01J together cover the great majority of records, confirming this is still primarily an optics-and-materials-analysis field. G06N appears in only 3.8% of records, C12M (bioreactors) in 3.4% — the software and apparatus layers around calibration itself are comparatively open.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to raman process monitoring calibration model, with the prior art for and against each one.
Who is filing, and where the gaps sit
The ranking spans instrument makers, diagnostics firms and pharmaceutical manufacturers, reflecting how calibration-model patenting spreads across hardware, bioprocessing and diagnostic use cases rather than sitting with one industry.
A modest lead, not a monopoly
The top-ranked assignee holds 44 of the 1,243 records in scope, roughly 3.5% of the total corpus — enough to lead the ranking but far short of dominating the claim space.
A long tail beyond the leaders
With the top 10 assignees together accounting for 22.1% of all records, close to four-fifths of filings sit outside the ranked leadership — spread across the 90 remaining ranked assignees and unranked single-filers.
Several established filers show no latest-year output
A number of assignees that appear high in the overall ranking, including instrumentation and pharmaceutical names, show zero filings in the latest tracked year. That reads as a lag in publication for very recent filings as much as a slowdown, given the 18-month publication delay.
| Assignee | Recent year | YoY |
|---|---|---|
| Johnson Matthey Plc | 0 | — |
| Regeneron Pharmaceuticals Inc | 0 | -100% |
| Becton, Dickinson and Company | 0 | — |
| Eastman Chemical Company | 0 | — |
| Cell Therapy Catapult | 0 | — |
| Viavi Solutions Inc | 0 | — |
| Massachusetts Institute of Technology | 0 | — |
| ChemImage Corp | 0 | — |
Where to take this next
The dataset points to specific follow-up questions rather than a single conclusion.
Track the 2025-2026 publication lag
Current filing figures for the most recent years will keep rising as applications publish. Revisit the trend once the 18-month lag has cleared to see whether the 2022 peak was a plateau or a genuine high point.
Explore filing trends in Eureka →Map the G06N-G01N overlap
Only 3.8% of records carry G06N alongside the dominant G01N class, suggesting AI-based calibration-model methods are still lightly claimed against the hardware base. That overlap is worth a dedicated search before committing claim language.
Run a targeted overlap search in Eureka →Watch the long tail for consolidation
With 22.1% of records held by the top 10 and the rest spread thinly, licensing or acquisition activity among smaller filers could shift concentration quickly. Monitor assignee-level momentum rather than relying on a single snapshot.
Set up assignee monitoring in Eureka →Common questions on this landscape
The leading assignee in this dataset holds 44 of the 1,243 records in scope, with the top 5 assignees combined accounting for 13.8% of all records and the top 10 reaching 22.1%. That means no single company controls the field; instead there is a modest leader followed by a long tail of assignees with far fewer filings each. The ranking spans 100 assignees drawn from instrumentation, diagnostics and pharmaceutical manufacturing backgrounds, so leadership varies depending on whether you weight by raw filing count or by recent-year activity.
Filings rose from 52 records in 2017 to a peak of 90 in 2022, then eased to 52 records by 2024, a 26% decline over that three-year span. However, 2025 and 2026 figures are still incomplete because publication typically lags actual filing by around 18 months, so those most recent years understate real activity rather than confirming a continued drop. The more defensible read is that 2022 was a high point and the field has settled to a somewhat lower but still active filing rate.
Almost the entire corpus, 99.4% of the 1,243 records, carries the G01N material analysis and testing classification, with G01J radiation and light measurement present in 29.4%. Life-science-adjacent classes appear at meaningfully lower but still notable rates: A61B diagnosis and surgery at 13.6%, C12Q enzyme/DNA measurement at 6.3%, and C12M bioreactor apparatus at 3.4%. AI-based computation under G06N appears in only 3.8% of records, indicating the software side of calibration modelling is comparatively lightly claimed against the optical hardware base.
The clearest gaps sit where spectroscopy hardware claims meet computational model maintenance: automated calibration transfer across different instrument units, AI-driven correction for model drift over time, and bioreactor-integrated probe configurations for continuous perfusion culture monitoring all show thin filing density relative to the core optics claims. A first claim in one of these areas would likely combine a specific Raman measurement configuration with a defined data-processing or validation step, rather than claiming either element alone. Given that G06N appears in only 3.8% of records, method claims tying spectral data to automated model updates are a genuinely under-filed combination.
This WuXi Biologics Ireland application, filed 2022-09-22, claims a bioreactor system with Raman probes immersed directly in the culture vessel and connected to a host computer that monitors and auto-controls perfusion cell culture. Its scope is centred on the specific combination of in-line probe placement, feed and bleed ports, and a cell retention system tied to real-time Raman feedback, rather than Raman monitoring of bioreactors in general. Anyone building a competing system should check whether their probe placement, control loop architecture, or retention mechanism differs materially from this specific combination before assuming freedom to operate.
Research Raman Process Monitoring Calibration Model in depth with Eureka
Go past this page: query the whole raman process monitoring calibration model corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.